Sumitomo Chemical Q1 2025 slides: core income surges despite revenue decline

Introduction & Market Context

Sumitomo Chemical (TYO:4005) presented its first quarter fiscal year 2025 financial results on August 1, 2025, revealing a significant improvement in core operating income despite facing headwinds in sales revenue. The company operates in a global economic environment showing signs of gradual recovery but still facing considerable uncertainty across various sectors.

The chemical giant reported mixed performance across its business segments, with particularly strong results in its pharmaceutical division offsetting challenges in other areas. Currency fluctuations, particularly the strengthening yen, continued to impact the company’s international operations.

Quarterly Performance Highlights

Sumitomo Chemical’s core operating income surged to 27.7 billion yen in Q1 FY2025, a substantial increase from 5.7 billion yen in the same period last year. This improvement demonstrates the company’s continued recovery trajectory from the -53.6 billion yen reported in Q1 FY2023.

However, the company reported a net income loss of 4.5 billion yen, a significant decline from the 24.4 billion yen profit recorded in Q1 FY2024. This downturn was primarily attributed to losses on foreign currency transactions.

As shown in the following comprehensive financial summary:

Sales revenue decreased to 526.1 billion yen, down from 612.1 billion yen in the previous year, representing a 14.0% decline. Despite this revenue contraction, operating income more than doubled to 25.5 billion yen compared to 11.5 billion yen in Q1 FY2024.

The company maintained a solid overseas sales revenue ratio of 53.5%, though this marked a slight decrease from 55.7% in the previous year. The exchange rate averaged 144.59 yen per USD during the quarter, compared to 137.42 yen per USD in Q1 FY2024.

Segment Analysis

Sumitomo Chemical’s business performance varied significantly across its five main segments, with Sumitomo Pharma emerging as the standout performer.

The breakdown of sales revenue by business segment reveals the scale of decline across most divisions:

The Essential & Green Materials segment experienced the most substantial revenue decline, dropping to 165.4 billion yen from 225.0 billion yen in Q1 FY2024. ICT & Mobility Solutions also saw a significant decrease to 137.4 billion yen from 152.7 billion yen. Conversely, Sumitomo Pharma was the only segment to show growth, increasing to 107.4 billion yen from 90.6 billion yen.

When examining core operating income by segment, the contrast becomes even more pronounced:

Sumitomo Pharma delivered exceptional performance with core operating income of 21.0 billion yen, a dramatic improvement from 0.9 billion yen in Q1 FY2024. This was primarily driven by expansion in drug sales and cost reduction measures. Meanwhile, the Essential & Green Materials segment showed significant improvement, reducing its loss to 5.5 billion yen from 19.6 billion yen in the previous year, benefiting from improved profit margins in synthetic resins and better refining margins at Petro Rabigh.

The ICT & Mobility Solutions segment reported core operating income of 18.4 billion yen, down from 21.2 billion yen, impacted by declining selling prices of polarizing films despite gain on sales from large LCD polarizing films.

In the crop protection business, the company noted solid growth in India, while the methionine market showed signs of recovery after bottoming out at the end of the previous fiscal year.

Financial Position and Cash Flow

Sumitomo Chemical’s consolidated statement of cash flows revealed improved operating cash flow generation:

Cash flow from operating activities turned positive at 24.0 billion yen, a significant improvement from the -12.3 billion yen reported in Q1 FY2024. However, investing activities consumed 45.9 billion yen, contrasting with the 82.5 billion yen generated in the previous year. As a result, free cash flow was negative at -21.9 billion yen, compared to a positive 70.2 billion yen in Q1 FY2024.

The company ended the quarter with cash and cash equivalents of 142.6 billion yen, substantially lower than the 234.3 billion yen reported at the end of the same period last year.

Forward-Looking Statements

Looking ahead to the first half of FY2025, Sumitomo Chemical provided an optimistic outlook:

The company forecasts sales revenue of 1,100.0 billion yen and core operating income of 90.0 billion yen for the first half of FY2025. Net income attributable to owners of the parent is expected to reach 25.0 billion yen, indicating a significant improvement in the second quarter.

The segment-specific outlook for the first half of FY2025 shows varied expectations:

Sumitomo Chemical anticipates particularly strong performance in Q2 for its Agro & Life Solutions and ICT & Mobility Solutions segments. The company expects continued contribution from Sumitomo Pharma and overall progress in improvement compared to FY2024.

However, management acknowledged potential challenges, particularly from currency fluctuations with the strong yen potentially impacting the ICT and Mobility Solutions segments. The global economic recovery remains uncertain, which could affect demand forecasts across various business lines.

As the company navigates these mixed market conditions, its focus on operational efficiencies and strategic positioning in high-growth segments appears to be yielding results, despite the ongoing challenges in the global chemical industry.

Full presentation:

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.